Clinical trials recruiting in Bremen, Germany

Phase breakdown

Conditions recruiting in Bremen, Germany

Recruiting trials in Bremen, Germany

• A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis
  NCT05344469 · Phase: Not specified · Ages: 18 Years to 100 Years · Sex: All (male and female)
• A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence
  NCT06830720 · Phase: Not specified · Ages: 18 Years to 100 Years · Sex: All (male and female)
• A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
  NCT06283966 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female)
• A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
  NCT07287098 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female
• A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
  NCT07169578 · Phase: Phase 3 · Ages: 50 Years to 90 Years · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
  NCT06976216 · Phase: Phase 3 · Ages: 60 Years to 85 Years · Sex: All (male and female)
• A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
  NCT07761117 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib
  NCT07237256 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Female
• Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management
  NCT05362760 · Phase: Phase 4 · Ages: 18 Years and older · Sex: Female
• Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients
  NCT05452213 · Phase: Phase 4 · Ages: 18 Years and older · Sex: Female
• Corheart 6 LVAS Study
  NCT05876000 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female)
• Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer
  NCT06207734 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female
• EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
  NCT07064473 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Efficacy and Safety of Oral Controlled-Ileocolonic-Release Nicotinamide (CICR-NAM) in Patients With Mild to Moderately Active Ulcerative Colitis
  NCT06488625 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
  NCT05512364 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• German Dementia Registry
  NCT07433010 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Health Surveillance at Constructor University Bremen (CUB) and Among HAW-Hamburg Employees
  NCT06899308 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
  NCT06112314 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Intensive Prevention Program After Decompensated Heart Failure
  NCT07472660 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 80 Years · Sex: All (male and female)
• Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC
  NCT07242352 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations
  NCT06494540 · Phase: Not specified · Ages: 18 Years to 120 Years · Sex: All (male and female)
• NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)
  NCT06081244 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Female
• PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS
  NCT05792150 · Phase: Not specified · Ages: 18 Years to 60 Years · Sex: Female
• Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
  NCT05232916 · Phase: Phase 3 · Ages: 18 Years to 100 Years · Sex: All (male and female)
• Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
  NCT06677060 · Phase: Phase 3 · Ages: 40 Years and older · Sex: All (male and female)
• Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)
  NCT05008809 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
  NCT00271180 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female)
• ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
  NCT07173751 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Register Schweres Asthma - German Asthma Net e.V.
  NCT06035289 · Phase: Not specified · Ages: 6 Years and older · Sex: All (male and female)
• Shift Workers' Health Behavior Action Program Across Europe
  NCT07631767 · Phase: Not applicable (e.g. observational or device study) · Ages: 21 Years and older · Sex: All (male and female)
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
  NCT05633654 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Study to Assess Real Life Effectiveness of Foslevodopa/Foscarbidopa in Adult German Participants at Initial Stages of Advanced Parkinson's Disease (EARLY-FOS)
  NCT06916507 · Phase: Not specified · Ages: 18 Years to 64 Years · Sex: All (male and female)
• TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study
  NCT05538806 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
  NCT07181109 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Bremen, Germany?

34 recruiting trials have at least one study site in Bremen, Germany.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.